Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCo-Diagnostics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$4.24 | -$3.26 | -$3.75 |
| Q2 2026 | 1 | -$3.39 | -$2.61 | -$3.00 |
| Q3 2026 | 1 | -$3.22 | -$2.48 | -$2.85 |
| Q4 2026 | 1 | -$3.05 | -$2.35 | -$2.70 |
| Q1 2027 | 1 | -$0.98 | -$0.76 | -$0.87 |
| Q2 2027 | 1 | -$0.99 | -$0.76 | -$0.88 |
| Q3 2027 | 1 | -$1.11 | -$0.85 | -$0.98 |
| Q4 2027 | 1 | -$1.37 | -$1.06 | -$1.22 |
| Q1 2028 | 1 | $4.11 | $5.35 | $4.73 |
| Q2 2028 | 1 | $4.27 | $5.56 | $4.91 |
| Q3 2028 | 1 | $4.18 | $5.44 | $4.81 |
| Q4 2028 | 1 | $4.17 | $5.42 | $4.80 |
Co-Diagnostics, Inc. Earnings Date And Information
Co-Diagnostics, Inc. last posted its earnings results on Thursday, November 13th, 2025. The company reported $-4.8 earnings per share for the quarter, topping analysts' consensus estimates of $-5.71 by $0.91. The company had revenue of 145.38 K for the quarter and had revenue of 3.92 M for the year. Co-Diagnostics, Inc. has generated $-37 earnings per share over the last year ($-37.2 diluted earnings per share) and currently has a price-to-earnings ratio of -0.11. Co-Diagnostics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 13th, 2025 based on prior year's report dates.
Co-Diagnostics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2025 | Q3 2025 | -$5.71 | -$4.66 | 1.05 | $300.00 K | $145.38 K |
| 08/14/2025 | Q2 2025 | -$0.25 | -$7.00 | -6.75 | $300.00 K | $162.91 K |
| 05/08/2025 | Q1 2025 | -$0.33 | -$7.05 | -6.72 | N/A | $50.28 K |
| 03/27/2025 | Q4 2024 | -$0.34 | -$10.01 | -9.67 | N/A | $149.33 K |
| 11/07/2024 | Q3 2024 | -$0.33 | -$9.54 | -9.21 | $375.00 K | $641.14 K |
| 08/08/2024 | Q2 2024 | -$0.34 | -$7.57 | -7.23 | $400.00 K | $2.66 M |
| 05/09/2024 | Q1 2024 | -$0.21 | -$9.36 | -9.15 | N/A | $252.75 K |
| 03/14/2024 | Q4 2023 | -$0.20 | -$14.10 | -13.9 | N/A | $3.56 M |
| 11/09/2023 | Q3 2023 | -$0.29 | -$6.11 | -5.82 | N/A | $2.46 M |
| 08/10/2023 | Q2 2023 | -$0.24 | -$9.20 | -8.96 | N/A | $197.81 K |
| 05/11/2023 | Q1 2023 | -$0.23 | -$5.86 | -5.63 | N/A | $601.96 K |
| 03/16/2023 | Q4 2022 | -$0.15 | -$21.30 | -21.15 | N/A | $1.40 M |
| 11/10/2022 | Q3 2022 | -$0.06 | -$1.31 | -1.25 | N/A | $5.09 M |
| 08/11/2022 | Q2 2022 | $0.15 | -$2.48 | -2.63 | N/A | $5.02 M |
| 05/12/2022 | Q1 2022 | $0.18 | $10.36 | 10.18 | N/A | $22.70 M |
| 03/24/2022 | Q4 2021 | $0.15 | $7.80 | 7.65 | N/A | $20.40 M |
| 11/12/2021 | Q3 2021 | N/A | $11.90 | N/A | N/A | $30.10 M |
| 08/12/2021 | Q2 2021 | $0.23 | $10.20 | 9.97 | N/A | $27.36 M |
| 05/13/2021 | Q1 2021 | $0.20 | $8.27 | 8.07 | N/A | $20.02 M |
| 03/25/2021 | Q4 2020 | $0.49 | $13.80 | 13.31 | N/A | $27.15 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Co-Diagnostics, Inc. Earnings: FAQ's
Co-Diagnostics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 13th, 2025 based offlast year's report dates.
In the previous quarter, Co-Diagnostics, Inc. (:CODX) reported $-4.8 earnings per share (EPS) to beat the analysts' consensus estimate of $-5.71 by $0.91.
The conference call for Co-Diagnostics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Co-Diagnostics, Inc.'s latest earnings report can be read online.
Co-Diagnostics, Inc. (:CODX) has a recorded annual revenue of $3.92 M.
Co-Diagnostics, Inc. (:CODX) has a recorded net income of $-37,639,008.Co-Diagnostics, Inc. has generated $-37.2 earnings per share over the last four quarters.
Co-Diagnostics, Inc. (:CODX) has a price-to-earnings ratio of -0.11 and price/earnings-to-growth ratio is -0.01.